EGFR (L792F/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.L792F;p.L858R
Components
p.L792Fp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.0% | 1.0% | 96.49 |
| 2 | Mobocertinib | 98.8% | 1.2% | 97.22 |
| 3 | Dacomitinib | 96.3% | 3.7% | 97.99 |
| 4 | Erlotinib | 96.3% | 3.7% | 99.75 |
| 5 | Osimertinib | 95.5% | 4.5% | 97.24 |
| 6 | Lazertinib | 94.4% | 5.6% | 97.47 |
| 7 | Neratinib | 93.2% | 6.8% | 93.18 |
| 8 | Vandetanib | 90.7% | 9.3% | 95.74 |
| 9 | Fostamatinib | 78.3% | 21.7% | 96.74 |
| 10 | Pralsetinib | 73.7% | 26.3% | 93.43 |
| 11 | Lapatinib | 68.9% | 31.1% | 99.25 |
| 12 | Pacritinib | 60.3% | 39.7% | 88.64 |
| 13 | Ibrutinib | 29.5% | 70.5% | 94.74 |
| 14 | Brigatinib | 26.3% | 73.7% | 82.96 |
| 15 | Dabrafenib | 20.9% | 79.1% | 94.74 |
| 16 | Trametinib | 17.4% | 82.6% | 99.50 |
| 17 | Ribociclib | 16.9% | 83.1% | 99.25 |
| 18 | Encorafenib | 15.4% | 84.6% | 98.50 |
| 19 | Alpelisib | 15.2% | 84.8% | 97.22 |
| 20 | Binimetinib | 14.4% | 85.6% | 100.00 |
| 21 | Pazopanib | 14.3% | 85.7% | 97.49 |
| 22 | Baricitinib | 14.0% | 86.0% | 97.99 |
| 23 | Deucravacitinib | 13.2% | 86.8% | 98.99 |
| 24 | Erdafitinib | 12.7% | 87.3% | 95.71 |
| 25 | Defactinib | 12.4% | 87.6% | 92.68 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.0% | 98.4% | +0.6% |
| Mobocertinib | 98.8% | 100.0% | -1.2% |
| Dacomitinib | 96.3% | 99.8% | -3.5% |
| Erlotinib | 96.3% | 99.4% | -3.1% |
| Osimertinib | 95.5% | 99.1% | -3.6% |
| Lazertinib | 94.4% | 100.0% | -5.6% |
| Neratinib | 93.2% | 100.0% | -6.8% |
| Vandetanib | 90.7% | 99.3% | -8.6% |
| Fostamatinib | 78.3% | 97.8% | -19.5% |
| Pralsetinib | 73.7% | 99.1% | -25.4% |
| Lapatinib | 68.9% | 99.2% | -30.3% |
| Pacritinib | 60.3% | — | — |
| Ibrutinib | 29.5% | 99.3% | -69.8% |
| Brigatinib | 26.3% | 98.5% | -72.2% |
| Dabrafenib | 20.9% | — | — |
| Trametinib | 17.4% | — | — |
| Ribociclib | 16.9% | — | — |
| Encorafenib | 15.4% | — | — |
| Alpelisib | 15.2% | — | — |
| Binimetinib | 14.4% | — | — |
| Pazopanib | 14.3% | — | — |
| Baricitinib | 14.0% | — | — |
| Deucravacitinib | 13.2% | — | — |
| Erdafitinib | 12.7% | — | — |
| Defactinib | 12.4% | 94.6% | -82.2% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms